- Investor's Business Daily•1 hour ago
Regeneron expects to top Amgen's recent heart-drug study in a team-up with Sanofi.
- American City Business Journals•2 hours ago
Shares of Burlington biotech Flexion Therapeutics soared to their highest point in more than a year and a half on Thursday following an unconfirmed report that French drug giant Sanofi is in talks to acquire the company for more than $1 billion. FiercePharma, citing an unnamed source, reported Thursday morning that the board of Flexion (FLXN) has voted to accept a non-binding offer from Sanofi (SNY), the parent company of Cambridge-based Sanofi-Genzyme. A Flexion spokesman declined comment, adding that the biotech will continue to pursue an “independent” strategy with its lead product, Zilretta, a long-acting steroid injection for osteoarthritis of the knee that could compete with one of Sanofi’s own treatments, Synvisc.
- TheStreet.com•4 hours ago
Flexion is an arthritis-focused biotech company.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||44.49 - 45.13|
|52 Week Range||36.81 - 45.13|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.01|
|Dividend & Yield||1.58 (3.56%)|
|1y Target Est||N/A|